Edition:
United Kingdom

Healios KK (4593.T)

4593.T on Tokyo Stock Exchange

2,048JPY
6:00am GMT
Change (% chg)

¥-58 (-2.75%)
Prev Close
¥2,106
Open
¥1,991
Day's High
¥2,049
Day's Low
¥1,892
Volume
978,200
Avg. Vol
164,347
52-wk High
¥2,196
52-wk Low
¥1,345

Chart for

About

HEALIOS K.K. is a Japan-based company mainly engaged in research and development of pharmaceutical products. The Company has compound pharmaceutical products line and induced pluripotent stem cell (iPSC) regenerative medicine product line. The compound pharmaceutical product line contains HLM0021, HLM0022 and HLM0023. The... (more)

Overall

Beta: --
Market Cap(Mil.): ¥68,843.38
Shares Outstanding(Mil.): 46.52
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 84.57 16.44
EPS (TTM): -- -- --
ROI: -- 3.42 10.61
ROE: -- 5.38 14.21

Tiny stem cell companies close in on major heart disease goals

NEW YORK The early hope that stem cell therapy would make the paralyzed walk, the blind see and cure diabetes have given way to a long list of failures, highlighted by early stem cell champion Geron Corp abandoning the field in 2011.

18 Dec 2017

RPT-Tiny stem cell companies close in on major heart disease goals

NEW YORK, Dec 18 The early hope that stem cell therapy would make the paralyzed walk, the blind see and cure diabetes have given way to a long list of failures, highlighted by early stem cell champion Geron Corp abandoning the field in 2011.

18 Dec 2017

Tiny stem cell companies close in on major heart disease goals

NEW YORK, Dec 18 The early hope that stem cell therapy would make the paralyzed walk, the blind see and cure diabetes have given way to a long list of failures, highlighted by early stem cell champion Geron Corp abandoning the field in 2011.

18 Dec 2017

BRIEF-Healios announces exercise of options

* Says 12,000 units of its tenth series options were exercised to 1.2 million shares of its common stock from Oct. 2 to Oct. 30

30 Oct 2017

Earnings vs. Estimates